Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gregory Moore

Interventional Pain Medicine Eugene, OR Medical Doctor

NPI 1457496705 CMS profile 293271

74B Centennial Loop, Suite 100, Eugene, OR 97401

Open in the dashboard

General payments

$377,163

796 records reported · program years 2019–2025

Research payments

$16

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,369,428 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Gregory Moore of Eugene, OR is reported in the CMS Open Payments database as having received $377,163 across 796 general payments and $16 in research payments paid to them. Separately, studies naming them as principal investigator received $1,369,428 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $71,438 103
2024 General $83,578 154
2023 General $53,022 158
2022 General $119,957 203
2021 General $41,322 98
2021 Research $16 1
2020 General $6,343 54
2019 General $1,504 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gregory Moore
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Gregory Moore were reported at $71,438. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Gregory Moore Interventional Pain Medicine median Middle half National median
2019 $1,504 $684 $216–$2,079 $163
2020 $6,343 $382 $122–$1,109 $114
2021 $41,322 $552 $167–$1,554 $132
2022 $119,957 $605 $187–$1,924 $149
2023 $53,022 $671 $195–$1,915 $160
2024 $83,578 $684 $206–$1,837 $164
2025 $71,438 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Relievant Medsystems, Inc. $159,283 163 payments
  2. Boston Scientific Corporation $133,883 224 payments
  3. Aurora Spine, Inc. $28,490 9 payments
  4. Medtronic, Inc. $15,821 78 payments
  5. Abbott Laboratories $14,644 173 payments
  6. MML US, Inc. $9,803 27 payments
  7. Vertos Medical, Inc. $7,744 6 payments
  8. Painteq LLC $3,114 31 payments
  9. Saluda Medical Americas, Inc. $1,478 15 payments
  10. Curonix LLC $590 7 payments
  11. Other $2,314 63 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $232,563 108 payments
  2. Consulting Fee $85,589 46 payments
  3. Travel and Lodging $31,979 106 payments
  4. Food and Beverage $19,959 527 payments
  5. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $3,600 1 payment
  6. Compensation for serving as faculty or as a speaker for a medical education program $2,450 2 payments
  7. Education $1,024 6 payments
Products named General payments · program years 2019–2025
  1. Intracept Pain $148,579 144 payments
  2. Intracept Pain $81,967 66 payments
  3. Intracept Pain $45,925 58 payments
  4. Intracept Pain $45,925 58 payments
  5. Intracept Pain $45,925 58 payments
  6. Intracept Contains (1)Intracept RF Probe (2)Intracept Access Instruments_NMOD $44,154 35 payments
  7. Intracept Pain $31,255 37 payments
  8. Intracept Pain $31,255 37 payments
  9. ZIP $28,490 9 payments
  10. Superion Indirect Decompression System $11,880 15 payments
  11. Other $70,253 488 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Saluda Medical Americas, Inc. $16 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

42

Median for Pain Management: 951

Drug cost

$696

Median for Pain Management: $26,034

Branded share of claims

0%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 27 $522
Oxycodone Hcl Generic 15 $175

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 88 billing codes

Paid by Medicare

$233,212

Of which drugs: $2,914

Medicare patients

690

Average age 74

Services billed

7,491

467 women, 223 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 70%
Depression 28%
Diabetes 25%
Chronic kidney disease 24%
Osteoporosis 23%
Ischemic heart disease 20%
COPD 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 70 3,900 $399
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 32 188 $140

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

797 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Oregon

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record